Another multicenter randomized trial (NCT05335928) is testing whether the early introduction of abatacept, a CTLA-4 agonist and T-cell inhibitor, improves major adverse cardiac event outcomes in patients with ICI-associated myocarditis. Here, CTLA4 is linked to myocarditis.